Furthermore, our findings suggest that LEFTY2 binds to and downregulates APOE4, offering an additional mechanism by which LEFTY2 could benefit Alzheimer’s disease pathology. Here, LEFTY2 is linked to early-onset autosomal dominant Alzheimer disease.